Portola Pharmaceuticals reports Q1 EPS ($1.28), consensus ($1.54) Reports Q1 revenue $6.6M, consensus $3.9M. Cash, cash equivalents and investments at March 31, 2018 totaled $451.1M, compared with cash, cash equivalents and investments of $534.2M as of December 31, 2017. Based on the FDA approval of Andexxa in May 2018, the company earned an additional $100M milestone payment from its royalty-based financing with Health Care Royalty Partners.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.